LEVY Health is a technology company.
LEVY Health has raised $8.0M across 2 funding rounds.
LEVY Health has raised $8.0M in total across 2 funding rounds.
LEVY Health has raised $8.0M in total across 2 funding rounds.
LEVY Health's investors include 8VC, Andreessen Horowitz, CRV, Dragonfly Capital Partners, J2 Ventures, Kohala Ventures, Lux Capital, Picus Capital, Pi Labs, Ravelin Capital, Village Global, VR Ventures.
# LEVY Health: Clinical Decision Support for Women's Reproductive Health
LEVY Health is a clinical decision support software company that helps reproductive health providers diagnose infertility and endocrine disorders faster and more accurately.[1][2] The company builds AI-powered tools that analyze patient questionnaires, biomarkers, and lab results to generate personalized diagnostic recommendations and treatment options before patients even visit the clinic.[6]
The company serves fertility clinics, egg donation agencies, and fertility benefits providers—essentially the entire B2B reproductive health ecosystem.[2] LEVY Health solves a critical bottleneck in women's healthcare: the diagnostic gap. Over 80% of endocrine disorders go undiagnosed or are diagnosed late, largely due to gaps in diagnostic training and guidance.[4] By automating the initial diagnostic workup, LEVY Health has achieved a 50% reduction in time to diagnosis for its customers, while freeing up clinician time for meaningful patient care.[6]
The company has demonstrated strong early traction, landing six B2B customers including Progyny (a major fertility benefits provider), Boston IVF (a fertility clinic chain), and Everie (an egg donation organization).[6] This customer validation is particularly significant in healthcare, where word-of-mouth trust is critical to adoption.
LEVY Health was founded in 2022 in Germany by Caroline Mitterdorfer (CEO & Co-Founder), Silvia Hecher (CPO & Co-Founder), and Dr. Theresa Vilsmaier (founding physician focused on gynecology).[3][6] Mitterdorfer's background in fertility advocacy brought her together with Hecher, who had held numerous roles in fertility clinics and companies, and Dr. Vilsmaier, whose clinical expertise grounded the product in real medical practice.[6]
The founding team quickly realized that the European market wasn't aligned with their business model—LEVY Health wanted to avoid passing costs to consumers, which conflicted with European healthcare economics.[6] This led to a pivotal pivot: the company relocated to the United States in 2023, where the B2B fertility clinic market was far more receptive to their software-as-a-service approach.[6] This geographic and market repositioning proved transformative, enabling rapid customer acquisition in the U.S. fertility ecosystem.
LEVY Health sits at the intersection of three powerful trends: AI-driven clinical decision support, the digitization of women's healthcare, and the consolidation of fertility services.
The company is riding the wave of AI adoption in healthcare, but with a crucial distinction: rather than deploying black-box machine learning models, LEVY Health starts with structured, rule-based algorithms grounded in medical guidelines, then feeds that structured data into larger AI models.[4] This approach addresses a fundamental challenge in women's health—data fragmentation and underdiagnosis—by first educating providers on what to test and when, creating the high-quality datasets needed for future AI advancement.[4]
The fertility and reproductive health market is experiencing significant consolidation and investment, driven by rising infertility rates, delayed childbearing, and the normalization of assisted reproductive technologies. LEVY Health's B2B model positions it to capture value across the entire ecosystem—from fertility clinics facing capacity constraints to benefits providers seeking to reduce time-to-treatment and improve member outcomes. The company's early customer wins (Progyny, Boston IVF, Everie) validate that the market is willing to pay for solutions that solve the diagnostic bottleneck.
LEVY Health is well-positioned to become the diagnostic backbone of the fertility and reproductive health industry. The company's vision extends beyond infertility: it aims to build longitudinal datasets that connect biomarkers, symptoms, and treatment outcomes to long-term disease risk, enabling early detection of autoimmune, metabolic, and cardiovascular diseases linked to hormonal health.[3] This expansion into broader women's health—moving from fertility-specific diagnostics to holistic hormonal health—could significantly expand the addressable market.
Key trends to watch: regulatory clarity around AI-based clinical decision support (some tools fall under FDA oversight, others do not), the continued consolidation of fertility services, and the growing emphasis on preventive care and early disease detection in women's health. As LEVY Health scales its customer base and accumulates richer datasets, the company's ability to deliver increasingly personalized, predictive recommendations could reshape how women access early diagnosis across their lifespans—fulfilling Mitterdorfer's stated mission to help "millions of women getting an early diagnosis."
LEVY Health has raised $8.0M across 2 funding rounds. Most recently, it raised $5.0M Seed in October 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2024 | $5.0M Seed | 8VC, Andreessen Horowitz, CRV, Dragonfly Capital Partners, J2 Ventures, Kohala Ventures, Lux Capital, Picus Capital, Pi Labs, Ravelin Capital, Village Global, VR Ventures, XYZ Venture Capital, Larry Braitman, Lawrence Braitman | |
| Mar 1, 2022 | $3.0M Seed | Antler, Atomico, Picus Capital, Privilège Ventures, XYZ Venture Capital, Jan Wilmking, Johann "Hansi" Hansmann, oliver holle, Travis Todd |